Theranostics：厦门大学林忠宁课题组发表鼻咽癌分子标志的筛查和靶向研究进展

2017-05-04 佚名生物帮

近日，国际生命及医学科学领域的权威学术期刊《Theranostics》杂志上在线发表了厦门大学公共卫生学院林忠宁教授团队题为《Downregulation of mitochondrial cyclooxygenase-2 inhibits the stemness of nasopharyngeal carcinoma by decreasing the activity of dynamin-

近日，国际生命及医学科学领域的权威学术期刊《Theranostics》杂志上在线发表了厦门大学公共卫生学院林忠宁教授团队题为《Downregulation of mitochondrial cyclooxygenase-2 inhibits the stemness of nasopharyngeal carcinoma by decreasing the activity of dynamin-related protein 1》的研究论文。硕士研究生周腾建是该本论文的第一作者，林忠宁教授和林育纯副教授是本论文的通讯作者。

研究关注于环氧合酶-2 (COX-2)调控鼻咽癌干性的线粒体动态学机制，探讨COX-2与p53参与线粒体质量控制的转录非依赖调控机制。研究通过分选鼻咽癌(NPC)细胞株中具有癌干性特征表型的侧群(SP)细胞与主群(MP)细胞对比，以及比较NPC组织与癌旁正常鼻咽上皮组织线粒体分裂调控分子Drp1与COX-2的表达水平，通过高表达与敲低表达NPC细胞COX-2，结果阐释了线粒体定位的COX-2通过与p53的互作、介导p53的线粒体转位和转录非依赖性调控功能，从而活化Drp1、增加线粒体分裂，诱导NPC细胞癌干性上调的分子机制。靶向干预线粒体COX-2和线粒体质量控制(MQC)靶分子Drp1，可经由抑制线粒体p53的转录非依赖性调控而降低鼻咽癌干性和增强抗肿瘤作用的敏感性。该研究首次证实了线粒体p53转录非依赖性调控参与了线粒体COX-2介导的线粒体动态及其MQC，并论证了线粒体COX-2是癌干性的潜在诊断与治疗靶点，为人群鼻咽癌化学预防潜在分子标志的筛查和靶向干预策略提供了科学依据。

原始出处：

Zhou TJ， Zhang SL， He CY，et al.Downregulation of mitochondrial cyclooxygenase-2 inhibits the stemness of nasopharyngeal carcinoma by decreasing the activity of dynamin-related protein 1.Theranostics 2017； 7(5)：1389-1406.

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言

评论区 (6)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1660662, encodeId=f16416606622c, content=<a href='/topic/show?id=803c3e216cf' target=_blank style='color:#2F92EE;'>#厦门#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37216, encryptionId=803c3e216cf, topicName=厦门)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a25130440, createdName=xqptu, createdTime=Sat Jun 10 08:21:00 CST 2017, time=2017-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049885, encodeId=b75d20498855f, content=<a href='/topic/show?id=852b1e3838b' target=_blank style='color:#2F92EE;'>#Theranos#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17383, encryptionId=852b1e3838b, topicName=Theranos)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3289320, createdName=海豹, createdTime=Thu Aug 10 13:21:00 CST 2017, time=2017-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738819, encodeId=0ed91e388192e, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Fri Oct 13 00:21:00 CST 2017, time=2017-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380790, encodeId=7b8d1380e9001, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Sat May 06 05:21:00 CST 2017, time=2017-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=193896, encodeId=d91f193896e7, content=好文，值得点赞，更值得收藏！慢慢领会学习的。给点个赞！, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Fri May 05 05:14:12 CST 2017, time=2017-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=193737, encodeId=2a1a193e37dd, content=这个是个不错的研究点, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Thu May 04 15:48:24 CST 2017, time=2017-05-04, status=1, ipAttribution=)]
2017-06-10 xqptu

#厦门#

29 0
[GetPortalCommentsPageByObjectIdResponse(id=1660662, encodeId=f16416606622c, content=<a href='/topic/show?id=803c3e216cf' target=_blank style='color:#2F92EE;'>#厦门#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37216, encryptionId=803c3e216cf, topicName=厦门)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a25130440, createdName=xqptu, createdTime=Sat Jun 10 08:21:00 CST 2017, time=2017-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049885, encodeId=b75d20498855f, content=<a href='/topic/show?id=852b1e3838b' target=_blank style='color:#2F92EE;'>#Theranos#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17383, encryptionId=852b1e3838b, topicName=Theranos)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3289320, createdName=海豹, createdTime=Thu Aug 10 13:21:00 CST 2017, time=2017-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738819, encodeId=0ed91e388192e, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Fri Oct 13 00:21:00 CST 2017, time=2017-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380790, encodeId=7b8d1380e9001, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Sat May 06 05:21:00 CST 2017, time=2017-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=193896, encodeId=d91f193896e7, content=好文，值得点赞，更值得收藏！慢慢领会学习的。给点个赞！, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Fri May 05 05:14:12 CST 2017, time=2017-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=193737, encodeId=2a1a193e37dd, content=这个是个不错的研究点, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Thu May 04 15:48:24 CST 2017, time=2017-05-04, status=1, ipAttribution=)]
2017-08-10 海豹

#Theranos#

30 0
[GetPortalCommentsPageByObjectIdResponse(id=1660662, encodeId=f16416606622c, content=<a href='/topic/show?id=803c3e216cf' target=_blank style='color:#2F92EE;'>#厦门#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37216, encryptionId=803c3e216cf, topicName=厦门)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a25130440, createdName=xqptu, createdTime=Sat Jun 10 08:21:00 CST 2017, time=2017-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049885, encodeId=b75d20498855f, content=<a href='/topic/show?id=852b1e3838b' target=_blank style='color:#2F92EE;'>#Theranos#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17383, encryptionId=852b1e3838b, topicName=Theranos)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3289320, createdName=海豹, createdTime=Thu Aug 10 13:21:00 CST 2017, time=2017-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738819, encodeId=0ed91e388192e, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Fri Oct 13 00:21:00 CST 2017, time=2017-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380790, encodeId=7b8d1380e9001, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Sat May 06 05:21:00 CST 2017, time=2017-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=193896, encodeId=d91f193896e7, content=好文，值得点赞，更值得收藏！慢慢领会学习的。给点个赞！, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Fri May 05 05:14:12 CST 2017, time=2017-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=193737, encodeId=2a1a193e37dd, content=这个是个不错的研究点, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Thu May 04 15:48:24 CST 2017, time=2017-05-04, status=1, ipAttribution=)]
2017-10-13 124988c7m106暂无昵称

#ERA#

30 0
[GetPortalCommentsPageByObjectIdResponse(id=1660662, encodeId=f16416606622c, content=<a href='/topic/show?id=803c3e216cf' target=_blank style='color:#2F92EE;'>#厦门#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37216, encryptionId=803c3e216cf, topicName=厦门)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a25130440, createdName=xqptu, createdTime=Sat Jun 10 08:21:00 CST 2017, time=2017-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049885, encodeId=b75d20498855f, content=<a href='/topic/show?id=852b1e3838b' target=_blank style='color:#2F92EE;'>#Theranos#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17383, encryptionId=852b1e3838b, topicName=Theranos)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3289320, createdName=海豹, createdTime=Thu Aug 10 13:21:00 CST 2017, time=2017-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738819, encodeId=0ed91e388192e, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Fri Oct 13 00:21:00 CST 2017, time=2017-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380790, encodeId=7b8d1380e9001, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Sat May 06 05:21:00 CST 2017, time=2017-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=193896, encodeId=d91f193896e7, content=好文，值得点赞，更值得收藏！慢慢领会学习的。给点个赞！, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Fri May 05 05:14:12 CST 2017, time=2017-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=193737, encodeId=2a1a193e37dd, content=这个是个不错的研究点, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Thu May 04 15:48:24 CST 2017, time=2017-05-04, status=1, ipAttribution=)]
2017-05-06 mashirong

#研究进展#

32 0
[GetPortalCommentsPageByObjectIdResponse(id=1660662, encodeId=f16416606622c, content=<a href='/topic/show?id=803c3e216cf' target=_blank style='color:#2F92EE;'>#厦门#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37216, encryptionId=803c3e216cf, topicName=厦门)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a25130440, createdName=xqptu, createdTime=Sat Jun 10 08:21:00 CST 2017, time=2017-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049885, encodeId=b75d20498855f, content=<a href='/topic/show?id=852b1e3838b' target=_blank style='color:#2F92EE;'>#Theranos#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17383, encryptionId=852b1e3838b, topicName=Theranos)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3289320, createdName=海豹, createdTime=Thu Aug 10 13:21:00 CST 2017, time=2017-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738819, encodeId=0ed91e388192e, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Fri Oct 13 00:21:00 CST 2017, time=2017-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380790, encodeId=7b8d1380e9001, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Sat May 06 05:21:00 CST 2017, time=2017-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=193896, encodeId=d91f193896e7, content=好文，值得点赞，更值得收藏！慢慢领会学习的。给点个赞！, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Fri May 05 05:14:12 CST 2017, time=2017-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=193737, encodeId=2a1a193e37dd, content=这个是个不错的研究点, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Thu May 04 15:48:24 CST 2017, time=2017-05-04, status=1, ipAttribution=)]
2017-05-05 ylzr123

好文，值得点赞，更值得收藏！慢慢领会学习的。给点个赞！

62 0
[GetPortalCommentsPageByObjectIdResponse(id=1660662, encodeId=f16416606622c, content=<a href='/topic/show?id=803c3e216cf' target=_blank style='color:#2F92EE;'>#厦门#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37216, encryptionId=803c3e216cf, topicName=厦门)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a25130440, createdName=xqptu, createdTime=Sat Jun 10 08:21:00 CST 2017, time=2017-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049885, encodeId=b75d20498855f, content=<a href='/topic/show?id=852b1e3838b' target=_blank style='color:#2F92EE;'>#Theranos#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17383, encryptionId=852b1e3838b, topicName=Theranos)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3289320, createdName=海豹, createdTime=Thu Aug 10 13:21:00 CST 2017, time=2017-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738819, encodeId=0ed91e388192e, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Fri Oct 13 00:21:00 CST 2017, time=2017-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380790, encodeId=7b8d1380e9001, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Sat May 06 05:21:00 CST 2017, time=2017-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=193896, encodeId=d91f193896e7, content=好文，值得点赞，更值得收藏！慢慢领会学习的。给点个赞！, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Fri May 05 05:14:12 CST 2017, time=2017-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=193737, encodeId=2a1a193e37dd, content=这个是个不错的研究点, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Thu May 04 15:48:24 CST 2017, time=2017-05-04, status=1, ipAttribution=)]
2017-05-04 131****2916

这个是个不错的研究点

51 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

肿瘤科

Theranostics：厦门大学林忠宁课题组发表鼻咽癌分子标志的筛查和靶向研究进展

相关资讯

科室

工具

服务